ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGEN Agenus Inc

10.238
-1.48 (-12.65%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agenus Inc NASDAQ:AGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.48 -12.65% 10.238 10.20 13.68 12.06 10.16 12.06 831,166 05:00:02

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

31/01/2024 12:30pm

Business Wire


Agenus (NASDAQ:AGEN)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Agenus Charts.

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Investors 917-362-1370 investor@agenusbio.com

Media 781-674-4784 communications@agenusbio.com

1 Year Agenus Chart

1 Year Agenus Chart

1 Month Agenus Chart

1 Month Agenus Chart

Your Recent History

Delayed Upgrade Clock